Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Georgi

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Stroke|September 28, 2019
Leveraging Human Genetics to Estimate Clinical Risk Reductions Achievable by Inhibiting Factor XIBenjamin Georgi, Johanna Mielke, Mark Chaffin, et al.
ERJ Open Research|February 25, 2026
FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthmaJonathan Corren, Fred Reid, Rachel Moate, et al.
Human Molecular Genetics|July 3, 2014
A population-based study of KCNH7 p.Arg394His and bipolar spectrum disorderKevin A Strauss, Sander Markx, Benjamin Georgi, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Stroke|September 28, 2019
Leveraging Human Genetics to Estimate Clinical Risk Reductions Achievable by Inhibiting Factor XIBenjamin Georgi, Johanna Mielke, Mark Chaffin, et al.
ERJ Open Research|February 25, 2026
FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthmaJonathan Corren, Fred Reid, Rachel Moate, et al.
Human Molecular Genetics|July 3, 2014
A population-based study of KCNH7 p.Arg394His and bipolar spectrum disorderKevin A Strauss, Sander Markx, Benjamin Georgi, et al.
Pageof 2